Good Business Based On Good Principles and Values
Managed by structure. Defined by passion.
The Board of Directors of Amarin Corporation plc sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfil its responsibilities and discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems them appropriate in the best interests of the Company or as required by applicable laws and regulations.
Articles of Association
Discover more about Amarin’s constitution, how we define the responsibilities of our directors, the kind of business we undertake, and the role of our stakeholders.
ADR List for 2025
Our Authorized Distributors of Record (ADR) lists distributors (for the U.S. only) with whom we have established an ongoing relationship to distribute products. View the full list here.
CA Declaration of Compliance
Our Declaration of Compliance states all the official rules we followed in our research and development. Discover more here.
Memorandum and Articles of Association
Want to know more about how Amarin regulates external affairs? Find out how our Memorandum complements our Articles of Association through the fundamental conditions under which we operate.
Code of Business Conduct and Policies
Follow our set of principles designed to guide our workers in conducting themselves with honesty and integrity in all actions representing the company.
Audit Committee Charter
The Audit Committee is appointed by the Board of Directors to oversee the accounting and financial reporting of the Company.
Nominating & Corp. Governance Comm. Charter
The Nominating and Corporate Governance Committee of the Board of Directors is responsible for identifying individuals qualified to become board members.
Remuneration Committee Charter
The Remuneration Committee is designated by the Board of Directors to set the compensation framework for the Board, CEO and other members of executive management.
Amarin Board Diversity Matrix
Please click the icon to download the Board Diversity Matrix
Board | Audit | Renumeration | NOM. & CORP. GOV. | |
|---|---|---|---|---|
Patrice Bonfiglio  |  |  | | |
Paul Cohen, M.D. | | | ||
Michael Torok | | |||
Keith L. Horn | |  | | |
Odysseas Kostas, M.D. | | | ||
Louis Sterling III | | | | |
Diane E. Sullivan | | | | |
Oliver O'Connor | | |
Director
Chairperson
Financial Expert
Independent Director
Investor Contact
For corporate governance, analyst coverage, stock information, secretarial matters and other investor-related queries, please use the Contact form
About Amarin for Investors
Amarin is a leading cardiovascular health pharmaceutical company. As leaders, we apply science, research, passion and global knowledge to ensure we further our vision of stopping cardiovascular disease from being a leading cause of death. In order to achieve this vision, we take a strategic approach to management and financial responsibility.
Financial Information
Learn about Amarin's revenue, expenses, profit and loss, and the company's financial health.
Analyst Coverage
Find out which firms and analysts are covering Amarin.
Stock Information
View real-time stock prices and stock quotes.
About Amarin
A new paradigm in cardiovascular health management
Amarin Corporation is focused on a BOLD vision to stop cardiovascular disease from being a leading cause of death. Find out more about our vision and how we lead the way to better care for those with cardiovascular disease.
Science and Health
Passionate about cardiometabolic science and health
Learn more about the science underpinning our product and research & development efforts to advance innovation in cardiovascular disease.
News and Media
Press releases, news, updates and statements
From reports and reviews to partnerships and innovations, find out more about Amarin's latest news and stories as they stand in the press.
ALL-NP-00016 1/23
©2025 Amarin Pharmaceuticals Ireland Limited. All rights reserved.
AMARIN, VASCEPA, VAZKEPA and REDUCE-IT names and logos are trademarks of Amarin Pharmaceuticals Ireland Limited. | ALL-NP-00014 1/23
Get In Touch
Whether you’re a patient, a healthcare professional or a job seeker, you can find the best way to contact us from the options below. We’d love to hear from you:
Follow Us
Follow Amarin on our social channels for the latest company news, product campaigns and industry updates:
You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information.
The information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders.
Amarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.
Certain statements made on this web site or in materials accessed in or through the investor relations section of our web site are "forward-looking statements," which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q.
This website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice.
This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates.
Information on this website may be revised without any prior notice.